High purity 99% factory price in stock Macitentan powder

High purity 99% factory price in stock Macitentan powder

Min.Order / FOB Price:Get Latest Price

1 Kilogram	FOB Price:USD 15.0000 -800.0000

1 Kilogram

FOB Price:USD 15.0000 -800.0000

Min.Order :1 Kilogram
Purity: 99% up
Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram,Other

Keywords

Macitentan factory price High purity 99%

Quick Details

Appearance:White powder
Application:in low tempreture
PackAge:1kg/bag ;5kg/drum:25KG/drum
ProductionCapacity:20|Metric Ton|Month
Storage:in low tempreture
Transportation:in low tempreture

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier .

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Why choose us

1. best quality in your requirement
2. competitive price in china market
3. mature technical support
4. professional logistic support
5. full experience of large numbers containers loading in chinese sea port
6. fast shipment by reputed shipping line
7. packing with pallet as buyer's special request
8. best service after shipment with email !
9. cargoes together with container after-sales service available
10. full experience in export
11. raw materials from chinese origin

Details:

Product Information

Product Name	macitentan
Synonyms	N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfami;macitentan;N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide;ACT 064992;ACT-064992;ACT-064992 / ACT064992;SulfaMide,N-[5-(4-broMophenyl)-6-[2-[(5-broMo-2-pyriMidinyl)oxy]ethoxy]-4-pyriMidinyl]-N'-propyl-;N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide Macitentan
CAS	441798-33-0
MF	C19H22Br2N6O4S
MW	590.295
EINECS	1308068-626-2

Usage

Macitentan is a non-chiral sulphadiazine derivative. In vitro studies have shown that it is an oral active antagonist of endothelin ETA and ETB receptor, which can block endothelin-induced vasoconstriction in trachea and aorta. Developed by Swiss company Actelion Pharmaceuticals and first marketed in the United States with FDA approval on October 18, 2013, it is mainly used to treat pulmonary hypertension (PAH) and its product name is Opsumit. Compared with other drugs for pahs, masititan can significantly reduce the morbidity and mortality of pahs patients mainly by slowing the progression of disease.